AcolpEH launches a video thanking Factor-H commitment to Colombian HD families

AcolpEH, the national HD patient association based in Bogota has been working with Factor-H for a few years in trying to develop aid programs to benefit the many affected families in Colombia. Based in Bogota, AcolpEH’s founder Janeth Mosquera issued a video recently where several of the families who received aid on behalf of Factor-H […]

Donations for the Colombian patients

in 2015, we were able to raise US $20,000 in donations from pharmaceutical companies, which is being allocated to a variety of projects in Colombia. The goal is to help the neediest families as well as invest in longer term projects, such as the creation of an audio-visual guide to show families how best to […]

Visit to Cetram and the day care center in Santiago, Chile

Claudia and I just returned from a wonderful trip to Santiago de Chile. We spoke about our work in Enroll-HD (together with Cristina Sampaio and Joe Giuliano from CHDI and Bernhard Landwehrmeyer from Ulm) and the current therapeutic strategies. Cetram is a wonderful center for movement disorders, headed by Dr. Pedro Chana. Right now, Cetram […]

Huntington’s Month in Argentina – and a concert to celebrate it!

Claudia has managed to stage an impressive array of meetings during the month of May to celebrate the people affected by Huntington’s disease in Argentina. Part of this calendar of activities include a symposium to expose the social and medical issues affecting people suffering from HD. Both Claudia and I, as well as several international […]

Brenda’s story

Brenda’s Story – as told by Claudia Perandones from Buenos Aires, Argentina I have a patient, called Daniel L., with Huntington’s disease, who is in a delicate condition because he can no longer move by himself and has to be fed by means of a gastrostomy tube. Daniel has a daughter, called Brenda, 13 years […]

Viruses and the brain

Viruses and the brain JAN25 2015 I am certain most of you would have heard that some of the therapies being developed for HD and other neurodegenerative indications involve the use of viruses to deliver a gene therapy agent. This is true in the case of HD, we are working with 3 companies that have […]

EN